ESP Pharma, Orphan Therapeutics deal

Orphan granted ESP marketing and distribution rights in the U.S. and Canada to intravenous terlipressin, a synthetic analog of vasopressin in Phase III testing to treat type 1 hepato-renal syndrome (H...